ASNRT — Arab Society of Nephrology and Renal Transplantation

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection

In addition, clinical studies investigating conversion from calcineurin inhibitors to co-stimulation therapies such as anti-CD40L antibodies may reduce dnDSAs and AMR. In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.

Category

Transplant

Source

Nephrology Dialysis Transplantation

Read the full abstract on PubMed

More from ASNRT News

Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.

All news · ASNRT home